|Articles|June 12, 2002

Cytogen launches brachytherapy product

Radiopharmaceutical developer Cytogen has commercially released a new brachytherapy implant for the treatment of localized prostate cancer. DraxImage, the radiopharmaceutical subsidiary of Draxis Health, developed the next-generation radioactive seed, called BrachySeed Palladium-103. This is the second such offering by Cytogen and DraxImage. The first, BrachySeed I-125 containing radioactive iodine, was launched in 2001. The BrachySeed products complement Cytogen's ProstaScint, a monoclonal antibody-based agent used to image the extent and spread of prostate cancer.

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Related to this article

October 5th, 2026

The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 2

In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.

October 5th, 2026

Security: A Way to Be Safe and Unproductive in Radiology

Has the barrage of passwords, PINs and authenticator apps gone around the bend to a point where it hampers efficiency and productivity?

October 4th, 2026

Diagnostic Imaging's Weekly Scan: September 27 — October 3

Catch up on the top radiology content of the past week.

October 3rd, 2026

Emerging Research Insights and New Advances in Neuroradiology

Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.

October 2nd, 2026

MRI, CT or Ultrasound: Which Modality Offers the Most Utility for Imaging of Pancreatic Cancer?

Magnetic resonance imaging offered a 29 percent higher sensitivity than CT for differentiating liver metastases, but CT provided 12 percent higher sensitivity than MRI for assessing vascular invasion, according to a new 40-study meta-analysis.

October 1st, 2026

Current Perspectives on Integrating AI into Radiology

In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.

October 1st, 2026

Raising Questions on the Prognostic Value of Fractional Flow Reserve from CCTA

Does fractional flow reserve (FFR) or quantitative plaque burden from CCTA provide greater prognostic insight into coronary disease?

September 30th, 2026

The Reading Room Podcast: Current Perspectives, Challenges and Possibilities with AI in Breast Imaging, Part 1

In the first of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD share insights on the utility of AI in breast imaging with respect to potential advantages, current concerns and future directions.